Fourpath Capital Management
ALNY icon

Fourpath Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fourpath Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-665
Closed -$200K – 227
2026
Q2 		$200K Sell
665
-26
-4% -$7.84K 0.03% 226
2026
Q1 		$229K Buy
+691
New +$235K 0.03% 200
2025
Q4 		– Sell
-483
Closed -$220K – 229
2025
Q3 		$220K Buy
+483
New +$197K 0.03% 217

Other funds holding ALNY

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
Portman Square Capital
Portman Square Capital London, United Kingdom $1.77B AUM 15.29% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return
PensionDanmark
PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Sumitomo Mitsui DS Asset Management
Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

Fourpath Capital Management's ALNY Position: Q3 2026 in Review

Fourpath Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 665 shares — an estimated $200K sold.

Fourpath Capital Management first reported a position in ALNY in Q3 2025 and held it in 3 quarters. The position peaked at $229K in Q1 2026. 128 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Fourpath Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Fourpath Capital Management sold 665 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $200K.
  • Fourpath Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Fourpath Capital Management's Alnylam Pharmaceuticals position peaked at $229K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Fourpath Capital Management's 13F filing for Q3 2026, filed 19 Oct 2026.